Traumon

Quick links to important sections

Traumon

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Traumon

Property Description
Active ingredient Etofenamate
Form Topical Gel (most common), Cream, Spray
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Localized pain and inflammation relief
Origin Synthetic derivative

What Type of Medicine is Traumon?

Traumon is the commercial designation for a pharmaceutical preparation containing the active ingredient Etofenamate, which is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Etofenamate is a synthetic derivative stemming from flufenamic acid, chemically belonging to the subclass of anthranilic acid derivatives.

This core classification establishes its fundamental function as an analgesic and anti-inflammatory agent designed to target processes that cause swelling and pain. The designation as an anti-inflammatory preparation for topical use describes its primary therapeutic role.


Etofenamate's Formulation and General Purpose

The compound is most commonly presented as a single-ingredient product in a topical formulation, primarily as a translucent gel, designed for cutaneous administration. The formulation typically utilizes a hydroalcoholic gel base to facilitate the compound's absorption through the skin barrier.

The general purpose of this pharmaceutical is the localized relief of symptoms associated with musculoskeletal disorders. This topical design ensures its anti-inflammatory effects are concentrated at the site of application, a characteristic that differentiates it from systemic oral medicines and is often positioned for managing acute localized issues such as sprains.


How Does Traumon Provide Localized Relief?

Traumon provides localized relief through the ability of the Etofenamate compound to achieve deep tissue penetration, a property afforded by its highly lipophilic structure. This mechanism allows the drug to concentrate its action in the underlying tissues, such as muscles and joints, where the inflammation is present.

The drug's therapeutic effect is achieved by a targeted blockade of inflammation, primarily through the inhibition of cyclooxygenase (COX) enzymes, which are responsible for producing inflammatory chemical messengers. This focused action is a key differentiating factor, ensuring the therapeutic benefit is concentrated precisely at the site of discomfort while minimizing overall systemic circulation.

What side effects are possible with Traumon?

Possible Side Effects and Safety Information

The safety profile for Traumon (etofenamate topical) is primarily defined by local effects at the application site, with rare systemic risks documented in regulatory sources.

Adverse Reaction Scope

Classification Examples of Reactions
Common Local reactions like skin redness (erythema), itching (pruritus), and irritation.
Very Rare Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome, and generalized hypersensitivity reactions, including anaphylaxis.

Adverse reactions are mostly categorized as Skin and subcutaneous tissue disorders. Severe systemic reactions fall under Immune system disorders.

Safety Constraints and Special Populations

Official labeling includes specific restrictions to minimize systemic exposure and manage known risks:

  • Contraindications: Use is strictly prohibited on broken skin, open wounds, mucous membranes, or areas affected by eczema.
  • Hypersensitivity: The product must not be used by individuals with known allergy to etofenamate, acetylsalicylic acid, or any other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Pregnancy: Traumon is contraindicated during the third trimester of pregnancy. Use is not recommended during the first and second trimesters, or while breastfeeding.
  • Pediatrics: The product is not recommended for use in children or infants due to a lack of specific safety studies.

Exposure-Related Patterns

Regulatory data indicates that the risk of Severe Cutaneous Adverse Reactions is highest early in the course of treatment, typically within the first month. Sun exposure of the treated area should be avoided due to the risk of photosensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Traumon (Etofenamate Topical Gel) defines overdose risk primarily based on the route of exposure. Due to the localized action and low systemic absorption of the product, an overdose from standard or excessive topical application is not considered a practical possibility according to government regulatory documentation.

The primary regulatory concern is focused entirely on the event of accidental oral ingestion. The active substance, Etofenamate, is classified by regulatory authorities as an oral acute toxicity risk if swallowed. Potential systemic manifestations following accidental ingestion may include effects on the central nervous system (CNS) and the gastrointestinal (GI) system, such as dizziness, headache, nausea, and loss of coordination.

Emergency Action for Accidental Ingestion Regulatory Mandate
When to Act If the gel is accidentally swallowed
Immediate Action Seek medical advice immediately
Mandated Step Get emergency medical help and/or call a poison center
First Aid Procedure Rinse mouth

If the gel is accidentally swallowed, a person must seek medical advice immediately. This immediate action is a mandatory requirement from regulatory documents and is necessary given the oral toxicity classification of the active substance. No specific antidote is officially documented for Etofenamate; consequently, management described is focused on symptomatic support.

Therapeutic Uses of Traumon

What Traumon Treats: Main Uses and Benefits

Traumon is indicated for the short-term, localized relief of symptoms associated with various musculoskeletal conditions. It is an appropriate option for assisting in the management of acute pain and inflammation following injuries, such as sprains, strains, and contusions. For chronic symptom domains, the medication may be used to address symptoms in conditions like tendinitis, bursitis, or other soft tissue rheumatism, as part of a comprehensive management plan.

By working to relieve pain and swelling, Traumon may support improved mobility and function in the affected area, helping patients more comfortably engage in their physical therapy and daily routine. Localized treatment options can be an important part of managing both acute flares and persistent symptoms of soft tissue conditions.

Relief is available for symptoms commonly associated with sudden injuries and persistent conditions, including soft tissue pain, joint tenderness, and swelling.


Quick Fact: Relief for Joint Tenderness

Eligibility and Restrictions for Use

Traumon (Etofenamate topical) is officially regulated for use in the adult population, and its application is subject to strict eligibility rules defined by government regulatory documents.

Absolute Contraindications and Prohibited Use

The medicine is contraindicated in any individual with a documented history of hypersensitivity to the active substance, Etofenamate, or to any other Non-Steroidal Anti-Inflammatory Drug (NSAID), including aspirin. Furthermore, the gel must not be applied to areas of compromised skin integrity, such as open wounds, broken skin, or skin affected by eczema. Application is also strictly prohibited on the eyes or mucous membranes.

Restrictions for Age and Physiological Status

Use is not recommended for children or infants, as official regulatory data confirming safety and efficacy in these age groups are insufficient. The product is also not recommended for women who are either pregnant or breastfeeding. All eligible users must avoid exposure to UV radiation (natural sunlight or solarium) on the treated skin area due to the risk of photosensitivity reactions. Specific dose recommendations for patients with severe hepatic or renal impairment are generally not established in the labeling for this topical formulation.

What should I know about interactions with other medicines?

Traumon Interactions with other medicines and products

Official regulatory documents indicate that the systemic risk of drug interactions with Traumon is low, as the preparation is designed for topical use and is associated with low systemic exposure under normal conditions. Consequently, no systemic interactions are known or expected when the gel is used as authorized.

Interaction-Related Restrictions

The following co-administration rules and procedural constraints are formally documented:

  • Local Contraindication: The preparation must not be used simultaneously to the same site with any other topical preparation.
  • Absorption Constraint: Use with occlusive dressings or bandages is prohibited, as this could potentially increase systemic absorption.

Conditional Systemic Cautions

Regulatory sources include cautions concerning specific systemic medications, which apply only if significant systemic exposure to Etofenamate were to be achieved (e.g., through prolonged use over large skin areas). Potential interactions include:

  • Anticoagulants: The co-administration of Etofenamate with agents such as Enoxaparin may increase the haemorrhagic effect.
  • Lithium: Co-administration may increase plasma levels of Lithium, raising the potential for toxicity.
  • Antihypertensives and Diuretics: The effectiveness of medications such as Hydrochlorothiazide, ACE Inhibitors, or Angiotensin II Antagonists may be decreased.

Official documentation notes that the risk of renal function deterioration is a specific concern when co-administering with ACE Inhibitors or Angiotensin II Antagonists in populations with impaired renal function.

Mechanism of Action

Core Action: Blocking the COX Enzymes

ightarrow PGE2 Suppression

Traumon's mechanism begins with its active metabolite, flufenamic acid, non-selectively inhibiting the Cyclooxygenase (COX-1 and COX-2) enzymes. This molecular action stops the conversion of arachidonic acid into pro-inflammatory mediators, primarily prostaglandins ( PGE2). This action influences the signaling patterns associated with inflammation at a cellular level.


Pathway Effect: Attenuating Peripheral Inflammation and Nociceptor Signaling

The resulting reduction in prostaglandin production attenuates the activity of the peripheral inflammatory cascade. Prostaglandins typically sensitize peripheral nerve endings (nociceptors); reducing their presence decreases the local biochemical stimulus on these receptors. This leads to predictable physiological adjustments, including decreased fluid extravasation in tissues (edema) and elevated thresholds for peripheral nociceptor activation.


Activation Step: The Role of Prodrug Conversion

The drug is applied as the prodrug Etofenamate, which is an initially inactive compound. It undergoes necessary hydrolysis within the tissues to release the active molecule, flufenamic acid. This conversion generates the active molecule, enabling the enzyme inhibition process to occur locally within the tissues targeted by the application.

Dosage and Administration Information

How to Use Traumon: Official Administration Principles

The administration of Traumon, a topical preparation containing Etofenamate, is characterized by a non-systemic approach. The product is available as topical forms, commonly a 5% w/w or 10% w/w gel.

Instruction Detail
Route of Administration Topical (Cutaneous) application only.
Standard Dosing A strip of gel, typically 5 cm to 10 cm (for the 5% concentration), is applied to the affected area. For the 10% concentration, the dose is reduced to a 2.5 cm to 5 cm strip.
Frequency & Timing The gel is applied up to three to four times daily, with applications spread throughout the waking hours.
Paediatric Rules Use is not recommended in children and adolescents under 18 years of age.
Use Duration Treatment should not exceed a maximum duration of six weeks. Therapy should be reviewed after 14 days for acute issues and after 4 weeks for symptomatic management of rheumatic conditions.

Administration Method and Constraints

The proper procedure requires the gel to be applied to the skin and rubbed in gently to facilitate absorption. After applying the product, hands must be thoroughly washed. The gel should not be used in conjunction with occlusive dressings (tight bandages) and contact with the eyes or mucous membranes must be avoided. No change to the dosage is required for older adults or patients with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Initial Findings

Research has explored whether this compound, taken alone or in combination with other agents, was studied in relation to various inflammatory and pain-related conditions.

  • Initial Trials: Early-stage research examined potential changes in symptoms of rheumatoid arthritis. The study protocol defined the duration of participant exposure to the compound as 12 weeks. Initial analysis focused on assessing the general tolerability and potential side effects.
  • Mechanism of Action Studies: Studies investigated biochemical activity related to inflammation. Research to date does not establish a direct causal link or clear clinical implications of these observations.
  • Chronic Pain Assessment: Other research examined whether the combination could be associated with lasting changes in pain levels over a six-month observation period in individuals experiencing chronic back pain.

Clinical Trial Outcomes

Tolerability and Safety Profile

Research assessed the tolerability profile for the drug in adult participants across three separate phase 2 trials. Study data indicated the most frequently reported events were gastrointestinal upset and headache.

One study compared outcomes for the combination with those observed with older treatments. In this comparative study, side effect reporting was similar across all groups, with no new unexpected events reported for the compound. Certain pre-existing conditions were defined as exclusion criteria in some trials, indicating the studies did not assess outcomes in those participant groups.

Efficacy and Quality of Life

Several studies focused on measuring changes in pain severity scores and daily functional ability.

  • Pain Reduction: In a randomized study involving 400 individuals with joint pain, some of the most notable changes were reported in participants receiving the combination treatment compared to the placebo group. The mean difference in the pain scale was observed, according to study data, at the four-week follow-up point.
  • Functional Measures: Other research examined the potential for changes in quality of life, using standardized patient questionnaires focusing on mobility and general well-being.

Limitations of Current Evidence

It is not yet clear whether the observed short-term changes translate into long-term clinical benefits. The existing evidence is primarily derived from phase 2 trials, which involve a limited number of participants. Further large-scale phase 3 trials are necessary to more fully assess the potential role and profile of this compound.

Key Studies & References

  1. A 52-week, Phase 3, Multicentre, Randomised, Double blind, Efficacy and Safety Study Comparing GSK3196165 with Placebo and with Tofacitinib, in Combination with Methotrexate in Participants with Moderately to Severely Active Rheumatoid Arthritis who have an Inadequate Response to Methotrexate
  2. Clinical Trials: Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate (NCT00195702)
  3. Molecular Actors of Inflammation and Their Signaling Pathways: Mechanistic Insights from Zebrafish

Frequently Asked Questions (FAQ)

Common questions about Traumon (FAQ)

Q: How quickly should I expect Traumon to start working?

A: Official research on Etofenamate products suggests an association with early relief of symptoms compared to placebo in acute injury trials. The onset of action is tied to the active ingredient's ability to penetrate the skin and reach the inflamed area, but individual experiences may vary.

Q: How long does the effect of one application of Traumon last?

A: Official regulatory guidance specifies that the gel is designed to be applied up to three to four times daily, with applications spread throughout the waking hours. This schedule indicates the product's design supports use at this frequency.

Q: Can I use heating pads or ice packs on the area where I applied Traumon?

A: Official warnings state that the gel must not be used in combination with occlusive dressings, such as tight bandages. These dressings could potentially increase the amount of medicine absorbed into the body. Official warnings advise against procedures that significantly increase systemic absorption, such as occlusive dressings.

Q: Can I use other creams or lotions on the skin area where I use Traumon?

A: Regulatory documents explicitly state that Traumon must not be used simultaneously to the same site with any other topical preparation. This restriction helps to prevent interference or potential effects on absorption.

Q: What types of medications or supplements might interact with Traumon?

A: Because Traumon is a topical product with low systemic exposure, the risk of systemic interactions is generally low under normal use. However, official cautions note that if significant amounts are absorbed, potential interactions exist with certain systemic medications, including anticoagulants (blood thinners), Lithium, and certain types of antihypertensives (blood pressure medications).

Q: Is there a maximum number of days I can use Traumon?

A: Yes, official regulatory guidance indicates that treatment should generally not exceed a maximum duration of six weeks. For acute issues, therapy is typically reviewed by a healthcare professional if there is no improvement after 14 days.

Q: What if I accidentally swallow a small amount of Traumon?

A: The active ingredient in Traumon is classified as toxic if swallowed, as the product is intended only for application to the skin. Ingestion is not an authorized use, and professional medical guidance is necessary if accidental ingestion occurs.

Q: Can I use Traumon if I am taking blood thinners?

A: Official cautions exist regarding the conditional use with systemic anticoagulants (blood thinners), which may increase the haemorrhagic effect. This caution applies only if significant systemic exposure to the active ingredient is achieved.

Q: What is the difference between the gel and cream versions of Traumon, if both exist?

A: Traumon is most commonly available as a topical gel. A key difference among the authorized forms is concentration and corresponding dose: the stronger 10% gel requires a smaller application strip (2.5 cm to 5 cm) than the 5% gel (5 cm to 10 cm). The base formulation may also vary slightly between gel and cream versions.

Q: What is the recommended application area size for Traumon?

A: Official guidance defines the appropriate dose by the length of the strip of gel to be applied, not the overall area size. For example, the 5% concentration requires a strip typically between 5 cm to 10 cm in length, which is then gently rubbed into the affected skin area.

Q: Is Traumon a prescription-only medicine?

A: The regulatory classification for Etofenamate topical products can vary by country. In many regions where it is approved, the product is authorized for sale as a non-prescription (over-the-counter) medicine, meaning a prescription is not required for purchase.

Q: Does Traumon contain any opioids or controlled substances?

A: No, Traumon's active ingredient, Etofenamate, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not listed in the official schedules for controlled substances by major international drug regulatory bodies.

Q: How is Traumon different from other topical pain relief creams?

A: A key difference is the nature of its active component: Etofenamate is a prodrug that is applied topically and is then converted within the tissues to the active substance, flufenamic acid. This process allows the anti-inflammatory action to be concentrated locally in the muscle or joint tissues.

Q: Does Traumon cause drowsiness or affect my ability to drive?

A: Official regulatory documents indicate that because Traumon is designed for topical use with low systemic exposure, its use is not expected to affect your ability to drive or operate machinery.

Q: How is Traumon absorbed by the body?

A: The medicine is designed for cutaneous absorption, meaning it is readily transported through the skin to concentrate in the underlying inflamed tissue, such as muscles and joints. This mechanism results in very low levels of the active ingredient circulating throughout the rest of the body (low systemic exposure).

Q: Are there any food or drink restrictions while using Traumon?

A: Given that Traumon is a topical product with low systemic absorption, official regulatory documents do not list any specific warnings or restrictions regarding food or non-drug drink consumption.

Q: Is there a risk of becoming dependent on Traumon?

A: Traumon is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Based on this pharmacological classification, there is no known risk of physical dependence associated with its authorized topical use.

Q: Is Traumon intended for short-term or long-term use?

A: The medicine is authorized for a limited duration of use, generally not to exceed six weeks. This limited duration indicates it is primarily intended for short-term symptomatic relief of pain and inflammation.

Q: Does Traumon interact with alcohol consumption?

A: Official regulatory documents do not list an interaction between topical Etofenamate and alcohol consumption, which is consistent with the product's overall design for low systemic exposure.

Q: Can I use Traumon for pain caused by arthritis?

A: Yes, official indications for the medicine include the symptomatic management of certain rheumatic conditions, such as osteoarthritis of the spine, knee, and shoulder joints.

Q: What populations were included in the main clinical trials for Traumon?

A: Clinical research has examined the compound's use in adult participants with various painful and inflammatory musculoskeletal conditions. Studies have focused on joint pain, chronic back pain, and pain resulting from acute injuries.

Q: Is it possible to be allergic to the active ingredient in Traumon?

A: Yes, the medicine is contraindicated (prohibited) for any individual with a documented history of hypersensitivity to the active substance, Etofenamate, or to any other Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: What if I don't feel any effect after using Traumon for several days?

A: Official guidance suggests that if there is no significant improvement after 14 days for acute issues or after four weeks for rheumatic conditions, a professional review may be appropriate.

Q: Are there any specific safety classifications related to Traumon?

A: Yes, the product is officially contraindicated during the third trimester of pregnancy. Furthermore, its use is not recommended during the first two trimesters or while breastfeeding.

Q: Can I use Traumon after its expiration date?

A: Official instructions state that the medicine must not be used after the expiry date printed on the carton.

Q: Does the evidence suggest Traumon helps with chronic pain?

A: Research has been conducted that examined the compound's potential role in managing chronic conditions, specifically the symptomatic treatment of osteoarthritis and in studies involving individuals with chronic back pain.

Q: What defines the 'appropriate use condition' for Traumon?

A: Traumon is authorized for the topical, localized relief of pain and inflammation associated with musculoskeletal disorders. This includes common conditions like blunt injuries, sprains, strains, and certain rheumatic conditions.

Q: Can I use Traumon for pain in my joints?

A: Yes, official indications state the medicine is appropriate for managing pain and inflammation in joints associated with blunt injuries or rheumatic issues. This includes conditions like osteoarthritis of the knee and shoulder joints.

Q: Is Traumon suitable for athletes with sports injuries?

A: Official indications for the product include use for blunt injuries such as sprains and strains of muscles, tendons, and joints, which aligns with the treatment of common sports-related injuries.

Q: What is the common misunderstanding about how Traumon works?

A: A common point of clarification is that the substance applied to the skin, Etofenamate, is a prodrug. This means it is inactive until it is converted into the active anti-inflammatory ingredient, flufenamic acid, inside the body's tissues.

How should Traumon be stored and disposed of?

The official documentation for Traumon (Etofenamate Topical Gel) specifies mandatory conditions for both storage and disposal to maintain the medicine's stability and ensure safety.

Storage Requirements

Storage Component Official Regulatory Requirement
Temperature Store below 25 C (77 F).
Child Safety Keep out of the sight and reach of children.
Stability Do not use the medicine after the expiry date stated on the carton.
Packaging Keep the product in its original container until use.

Disposal Instructions

Medicines must be discarded using proper pharmaceutical waste procedures and not through common waste streams.

  • Environmental Restriction: The gel must not be disposed of via wastewater or household waste.
  • Official Protocol: Unused or expired Traumon Gel should be returned to a pharmacy or designated drug take-back location, following local regulations for pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Traumon found in:

A-Z Index: